Naftin®

References:

1. Stoughton RB, Sefton J, Zeleznick L. In vitro and in vivo cutaneous penetration and antifungal activity of naftifine. Cutis. 1989;44:333-335.

2. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Physician. 2002;65:2095-2102.

3. Zaias N, Astorga E, Cordero CN, et al. Naftifine cream in the treatment of cutaneous candidiasis. Cutis. 1988;42:238-240.

4. Gip L, Brundin G. A double-blind, two group multicentre study, comparing naftifine 1% cream with placebo cream in the treatment of tinea cruris. Mykosen. 1987;30(suppl 1):38-41.

5. Data on file, NAFT-216-7170, Merz Pharmaceuticals.

6. Monk JP, Brogden RN. Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatophytoses. Drugs. 1991;42:659-672.

7. Tronnier H. Inflammatory dermatomycoses – comparative study of naftifine and a combination of a corticosteroid and an imidazole derivative. Mykosen. 1987;30(suppl 1):78-87.

8. Jung EG. The anti-inflammatory efficacy of naftifine as evaluated from the erythema response to ultraviolet light. Mykosen. 1987;30(suppl 1):88-91.

9. Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol. 1997;36:788-792.

10. Goldstein BG, Goldstein AO. Practical Dermatology. Baltimore, MD: Mosby – Year Book, Inc; 1992:15-16.

11. Bennett JE. Antifungal agents. In: Mandell GL, Bennett JE, Dolin RD, eds. Principles and Practice of Infectious Diseases . 4th ed. New York, NY: Churchill Livingstone; 1995:401-410.

12. Mühlbacher JM. Naftifine: a topical allylamine antifungal agent. Clin Dermatol. 1992;9:479-485.